Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae

Journal of Hypertension

Volumn 28, Issue 2, 2010, Pages 361-366

  Fedorova, Olga V ^a   Tapilskaya, Natalia I ^c   Bzhelyansky, Anton M ^b   Frolova, Elena V ^d   Nikitina, Elena R ^d   Reznik, Vitaly A ^c   Kashkin, Vladimir A ^a   Bagrov, Alexei Y ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c State Pediatric Medical Academy   (Russian Federation)

^d SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

Digibind; Marinobufagenin; Na K ATPase; Ouabain; Placenta; Preeclampsia; Therapeutic antibody

Indexed keywords

BUFADIENOLIDE DERIVATIVE; CARDENOLIDE DERIVATIVE; DIGOXIN ANTIBODY F(AB) FRAGMENT; MARINOBUFAGENIN; OUABAIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ELUTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOREACTIVITY; PREECLAMPSIA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 75149186131     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328333226c     Document Type: Article

References (28)

1. Sibai BDekker GKupferminc M. Preeclampsia, Lancet, 2005 365 785-799.
2. Bagrov AY, Shapiro JI. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008; 4:378-392.
3. Gusdon JPJr, Buckalew VM Jr, Hennessy JF. A digoxin-like immunoreactive substance in preeclampsia. Am J Obstet Gynecol 1984; 150:83-85.
4. Graves SW, Valdes R Jr, Brown BA, Knight AB, Craig HR. Endogenous digoxin-immunoreactive substance in human pregnancies. J Clin Endocrinol Metab 1984; 58:748-751.
5. Goodlin RC. Antidigoxin antibodies in eclampsia. N Engl J Med 1988; 318:518-559.
6. Adair CD, Buckalew V, Taylor K, Ernest JM, Frye AH, Evans C, Veille JC. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol 1996; 16:529-531.
7. Adair CD, Luper A, Rose JC, Russell G, Veille JC, Buckalew VM. The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. J Perinatol 2009; 29:284-289.
8. Lam G, Johnson D, Robinson C, Saade G, Lewis D, Porter K, et al. Antepartum administration of a digoxin immune Fab (Digibind1) improves renal function in patients with severe preeclampsia. Proceedings of XVI Congress of International Society for the Study of Hypertension in Pregnancy. Washington DC. 2008; 44:60.
9. Manunta P, Ferrandi M, Bianchi G, Hamlyn JM. Endogenous ouabain in cardiovascular function and disease. J Hypertens 2009; 27:9-18.
10. Bagrov AY, Fedorova OV, Dmitrieva RI, Howald WN, Hunter AP, Kuznetsova EA, Shpen VM. Bufodienolide nature of endogenous inhibitor of Na/K ATPase in the urine from patients with acute myocardial infarction. Hypertension 1998; 31:1097-1103.
11. Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem 2005; 38:36-45.
12. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17:1179-1187.
13. Averina IV, Tapilskaya NI, Reznik VA, Frolova EV, Fedorova OV, Lakatta EG, Bagrov AY. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol (Noisy-le-grand) 2006; 52:19-23.
14. Fedorova OV, Simbirtsev AS, Kolodkin NI, Kotov AY, Agalakova NI, Kashkin VA, et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens 2008; 26:2414-2425.
15. Pullen MA, Brooks DP, Edwards RM. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids. J Pharmacol Exp Ther 2004; 310:319-325.
16. Di Grande A, Boura AL, Read MA, Malatino LS, Walters WA. Release of a substance from the human placenta having digoxin-like immunoreactivity. Clin Exp Pharmacol Physiol 1993; 20:603-607.
17. Hilton PJ, White RW, Lord GA, Garner GV, Gordon DB, Hilton MJ, et al. An inhibitor of the sodium pump obtained from human placenta. Lancet 1996; 348:303-305.
18. National Institutes of Health Working Group on Hypertension in Pregnancy. Classification of hypertensive disorders of pregnancy. Bethesda, MD: US Dept. of Health and Human Services; 1991.
19. Fedorova OV, Zhuravin IA, Agalakova NI, Yamova LA, Talan MI, Lakatta EG, Bagrov AY. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor. J Hypertens 2007; 25:1834-1844.
20. Fedorova OV, Kolodkin NI, Agalakova NI, Namikas AR, Bzhelyansky A, St-Louis J, et al. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 2005; 23:835-842.
21. Armler E, Cester N, Salvolini E, Staffolani R, Burkhard M, Mazzanti L, et al. Human hypertensive placenta contains an increased amount of Na,K-ATPase with higher affinity for cardiac glycosides. Cell Biol Int 1994; 18:723-727.
22. Adair CD, Haupert GT Jr, Koh HP, Wang Y, Veille JC, Buckalew V. Erythrocyte sodium/potassium ATPase activity in severe preeclampsia. J Perinatol 2009; 29:280-283.
23. Akimova OA, Bagrov AY, Lopina OD, Kamernitsky AV, Tremblay J, Hamet P, Orlov SN. Cardiotonic steroids differentially affect intracellular Na\+ and [Na\+]i/[K\+]i-independent signaling in C7-MDCK cells. J Biol Chem 2005; 280:823-829.
24. Fedorova LV, Raju V, El-Okdi N, Shidyak A, Kennedy DJ, Vetteth S, et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition. Am J Physiol Renal Physiol 2009; 296:F922-F934.
25. Butler VP Jr, Morris JF, Akizawa T, Matsukawa M, Keating P, Hardart A, Furman I. Heterogeneity and lability of endogenous digitalis-like substances in the plasma of the toad, Bufo marinus. Am J Physiol 1996; 271:R325-R332.
26. Brubacher JR, Lachmanen D, Ravikumar PR, Hoffman RS. Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Toxicon 1999; 37:931-942.
27. Dasgupta A, Szelei-Stevens KA. Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol 2004; 121:276-281.
28. Pullen MA, Harpel MR, Danoff TM, Brooks DP. Comparison of nondigitalis binding properties of digoxin-specific Fabs using direct binding methods. J Immunol Methods 2008; 336:235-241.